.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, people with metastatic gastrointestinal lumps that obtained biomarker-matched therapies based on flowing growth DNA profiling revealed a more significant medical perk than those receiving unrivaled therapy.